Advertisement

Topics

Nivolumab Approved for Liver Cancer

10:31 EDT 25 Sep 2017 | Medscape

The FDA has approved the immunotherapy for use in patients with hepatocellular carcinoma who have previously been treated with sorafenib.
FDA Approvals

Original Article: Nivolumab Approved for Liver Cancer

NEXT ARTICLE

More From BioPortfolio on "Nivolumab Approved for Liver Cancer"

Give dad the gift of knowledge. Order his DNA Ancestry kit this Father's Day for $99 at 23andMe! Ord

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.